glp burst 1 InfoComm 2025: German Light Products GmbH Shows Off JDC Hybrid LED Strobe Light Taking a look back at

Symptomatic and Asymptomatic Hypoglycemia Post Three Different Bariatric Procedures: A Common and Severe Complication

What are the main formulation challenges in oral peptide development

Antagonistic targeting of the histamine H3 receptor decreases caloric intake in higher mammalian species

In September 2025, the FDA sent thousands of warning letters and issued approximately 100 cease-and-desist letters to companies regarding their use of misleading direct-to-consumer pharmaceutical advertisements. The agency also published a green list of acceptable GLP-1 compounding ingredients intended to regulate ingredient sourcing and reduce the risk of unsafe compounded products

Conclusion The rise of GLP-1 therapies has transformed what is possible in diabetes care

Effekten av kronisk bruk av GLP-1-analoger virker trygg, bl.a